Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

Wojciech Jurczak

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

Tara Graff

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

Georg Lenz

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

SOHO Highlights: State of the Art and Next Questions

G. Nowakowski

State of the Art and Next Questions: B-Cell Lymphoma

SOHO Highlights: State of the Art and Next Questions

L. Nastoupil

Frontline DLBCL Treatment Approaches

MyCancerHaven

R. Vij, H. Cherng

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Bispecifics for LBCL: Guidance for Management of Toxicities in the C…

UChicago Medicine

J. Crombie

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

Considering Alternatives to CAR-T in R/R DLBCL

Julio Chavez

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Moffitt Cancer Center

A. Lazaryan